drugset / Trial / NCT04606602
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
RandomizedParallel-groupDouble-blindPrevention
Summary
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
Timeline
- Start
- 2020-11-18
- Primary completion
- 2023-08-23
- Completion
- 2023-08-23
Publications
- Results Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. 2022 May 3;327(17):1679-1687. doi: 10.1001/jama.2022.5050.
- Results Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, Rider DA, Cho L, Romano S, Melgaard C, Rambaran C. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2024 May 14;331(18):1534-1543. doi: 10.1001/jama.2024.4504.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zerlasiran | Small interfering RNA (siRNA) | 30 mg | Subcutaneous |
| Subject | zerlasiran | Small interfering RNA (siRNA) | 100 mg | Subcutaneous |
| Subject | zerlasiran | Small interfering RNA (siRNA) | 200 mg | Subcutaneous |
| Subject | zerlasiran | Small interfering RNA (siRNA) | 300 mg | Subcutaneous |
| Subject | zerlasiran | Small interfering RNA (siRNA) | 600 mg | Subcutaneous |
| Subject | zerlasiran | Small interfering RNA (siRNA) | 900 mg | Subcutaneous |